Search Medical Condition
Please enter condition
Please choose location
 

Coronado, California Clinical Trials

A listing of Coronado, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (714) clinical trials

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

Phase

0.63 miles

Learn More »

Safety and Efficacy of Selonsertib GS-0976 GS-9674 and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

The primary objectives of this study are: To assess the safety and tolerability of selonsertib (SEL), GS-0976, and GS-9674, administered alone or in combination, in participants with bridging fibrosis or compensated cirrhosis due to Nonalcoholic Steatohepatitis (NASH) To evaluate changes in liver fibrosis, without worsening of NASH

Phase

0.63 miles

Learn More »

Safety Tolerability and Pharmacodynamics of SYNB1020

This study consists of two parts: Part 1: A sentinel open-label cohort of subjects with cirrhosis and Model for End-Stage Liver Disease (MELD) score <12 will be admitted to an inpatient facility for a run in diet, baseline assessments, IP administration, safety monitoring, and collection of blood, urine, and fecal ...

Phase

0.63 miles

Learn More »

Randomized Open-Label Multicenter Controlled Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91. The secondary objective is to evaluate the proportion of survivors at Study Day 91 ...

Phase

0.85 miles

Learn More »

Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

Primary To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 8 weeks of treatment Secondary To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 12 and 26 weeks of treatment To evaluate the safety and efficacy ...

Phase

0.85 miles

Learn More »

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis

Phase

0.85 miles

Learn More »

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

The study will consist a Screening Phase (up to 4 months) followed by a Treatment Phase (12 weeks), and a Follow-up visit (within 1 week after the last dose). A total of 40 male and female subjects 18 years of age are planned to be enrolled. During the Screening Phase, ...

Phase

0.85 miles

Learn More »

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

Phase

0.85 miles

Learn More »

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

The purpose of this study is to determine if the investigational treatment volixibat (SHP626) is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).

Phase

0.85 miles

Learn More »

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

The purpose of the study is to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Phase

0.85 miles

Learn More »